Nyere principper og muligheder inden for astmabehandling

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Nyere principper og muligheder inden for astmabehandling. / Janner, Julie H; Ulrik, Charlotte Suppli.

In: Ugeskrift for Laeger, Vol. 169, No. 11, 2007, p. 995-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Janner, JH & Ulrik, CS 2007, 'Nyere principper og muligheder inden for astmabehandling', Ugeskrift for Laeger, vol. 169, no. 11, pp. 995-7.

APA

Janner, J. H., & Ulrik, C. S. (2007). Nyere principper og muligheder inden for astmabehandling. Ugeskrift for Laeger, 169(11), 995-7.

Vancouver

Janner JH, Ulrik CS. Nyere principper og muligheder inden for astmabehandling. Ugeskrift for Laeger. 2007;169(11):995-7.

Author

Janner, Julie H ; Ulrik, Charlotte Suppli. / Nyere principper og muligheder inden for astmabehandling. In: Ugeskrift for Laeger. 2007 ; Vol. 169, No. 11. pp. 995-7.

Bibtex

@article{249b26ce6cac4cdd8581844c09bd4d0e,
title = "Nyere principper og muligheder inden for astmabehandling",
abstract = "In the coming years, asthma therapy should be tailored to the individual patient's needs. The principles of optimal asthma control and symptom-driven therapy offer the possibility for more individualised asthma management. Omalizumab (monoclonal anti IgE) may have positive clinical effects, including a reduction in the exacerbation-rate, and is indicated for patients, who--in spite of best possible asthma therapy--continue to have reduced lung function, severe exacerbations, severe symptoms, and documented non-seasonal allergy.",
author = "Janner, {Julie H} and Ulrik, {Charlotte Suppli}",
year = "2007",
language = "Dansk",
volume = "169",
pages = "995--7",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "11",

}

RIS

TY - JOUR

T1 - Nyere principper og muligheder inden for astmabehandling

AU - Janner, Julie H

AU - Ulrik, Charlotte Suppli

PY - 2007

Y1 - 2007

N2 - In the coming years, asthma therapy should be tailored to the individual patient's needs. The principles of optimal asthma control and symptom-driven therapy offer the possibility for more individualised asthma management. Omalizumab (monoclonal anti IgE) may have positive clinical effects, including a reduction in the exacerbation-rate, and is indicated for patients, who--in spite of best possible asthma therapy--continue to have reduced lung function, severe exacerbations, severe symptoms, and documented non-seasonal allergy.

AB - In the coming years, asthma therapy should be tailored to the individual patient's needs. The principles of optimal asthma control and symptom-driven therapy offer the possibility for more individualised asthma management. Omalizumab (monoclonal anti IgE) may have positive clinical effects, including a reduction in the exacerbation-rate, and is indicated for patients, who--in spite of best possible asthma therapy--continue to have reduced lung function, severe exacerbations, severe symptoms, and documented non-seasonal allergy.

M3 - Tidsskriftartikel

VL - 169

SP - 995

EP - 997

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 11

ER -

ID: 48598088